GENERAL
VIROLOGY
Prince AM, Brotman B, Richard L,
White T, Pollack N, Riddle J.
Incidence of hepatitis A virus (HAV) infection in rural Liberia. J
Med Virol
15: 421-428, 1985. [205]
Williams B, Prince AM, Huima T, Brotman
B. Spuma viruses isolated from
sources containing agents of non-A, non-B hepatitis (NANB) do not cause NANB
hepatitis. J Med Virol 24: 263-274, 1988.
[229]
Marx PA, Yen L, Lerche
NW, Sutjipto S, Gettie A, Yee JA, Brotman BH, Prince AM, Hanson A, Webster RG,
Desrosiers RC. Isolation of a
simian immunodeficiency virus related to human immunodeficiency virus type 2
from a West African sooty mangabey. J Virol 65(8):
4480-4485, 1991. [266]
HEPATITIS B
VIRUS
Prince AM. Hepatitis associated antigen: Long term
persistence in chimpanzees. In ŅMedical PrimatologyÓ (1970) Basel: Karger, pp.
731, 1971. [38]
Prince AM. Immunologic distinction between I.H.
and S.H. Editorial. N Engl J
Med
281: 163-164, 1969. [41]
Prince AM, Hargrove RL, Szmuness
W, Cherubin CE, Fontana VJ, Jefferies GH.
Immunologic distinction between infectious and serum hepatitis. N
Engl J Med
282: 987-991, 1970. [42]
Vnek J, Prince AM, Hashimoto N, Ikram
H. Association of normal serum
protein antigens with chimpanzee hepatitis B surface antigen particles. J
Med Virol
2:319-333, 1978. [137]
Krawczynski K, Prince
AM,
Nowoslawski A. Immunopathologic
aspects of the HBsAg carrier state in chimpanzees. J Med Primatol 8:222-232, 1979. [150]
Prince AM, White T, Pollock N,
Riddle J, Brotman B, Richardson L.
The epidemiology of hepatitis B infections in Liberian infants. Infection
and Immunity,
May 32:675-680, 1981. [156]
Stephan W, Prince AM, Brotman B. Modulation of hepatitis B infection by intravenous application of an immunoglobulin preparation that contains antibodies to hepatitis B and core antigens but not to hepatitis B surface antigen. J Virol 51:420-424, 1984. [189]
Brotman B, Prince AM. Occurrence of Ausab test positivity
unrelated to prior exposure to hepatitis B virus. J Infect Dis 50:714-720, 1984. [192]
Berthelot P, Courouce
AM, Eyquem A, Feldmann G, Jacob J, Ravisse P, Vacher B, Moor-Jankowski J,
Muchmore E, Prince AM. Hepatitis B
vaccine safety monitoring in the chimpanzee: Interpretation of results. J
Med Primatol
13:119-133, 1984. [194]
Neurath AR, Kent SBH,
Parker K, Prince AM, Strick N, Brotman B, Sproul P. Antibodies to a synthetic peptide form the PreS 120-145
region of the hepatitis B virus envelope are virus-neutralizing. Vaccine 4:35-37, 1986. [214]
Takahashi K, Brotman B, Usuda S, Mishiro S, Prince
AM. Full-genome sequence analyses of
hepatitis B virus (HBV) strains recovered from chimpanzees infected in the
wild: implications for an origin of HBV. Virology 267: 58-64, 1999. [335]
Prince AM, Lee D-H, Brotman B. Infectivity of blood from PCR-positive,
HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 41: 329-332, 2001.
[340]
Pancholi P, Lee D-H, Liu Q, Tackney C, Taylor P,
Perkus M, Andrus L, Brotman B, Prince AM.
Immunotherapy of chronic hepatitis B virus infection. Proceedings of the 10th
International Symposium on Viral Hepatitis and Liver Disease, International Medical
Press Ltd., Atlanta, GA, pp. 196-199, 2002. [349]
Ganem D, Prince AM. Hepatitis B virus infection --- natural
history and clinical consequences.
NEJM
350(11):1118-1129, 2004. [354]
HEPATITIS B
VACCINE
Prince AM, Vnek J. A new candidate hepatitis B vaccine
containing sub particulate HBsAg and HBeAg. In Touraine J.L. et al., (Eds.):
ŅTransplantation and Clinical Immunology,Ó Amsterdam: Excerpta Medical
10:90-97, 1979. [142]
Prince AM, Vnek J. A new candidate hepatitis B vaccine
containing sub particulate HBsAg and HBeAg. In E.S. Ketiladze (Eds.): ŅViral
Hepatitis A and B. Collection of
Papers,Ó Moscow: The D.I. [143]
Prince AM, Brotman B, van den
Ende MC. Evaluation of safety and
efficacy of bivalent NIH vaccine in chimpanzees. Proceedings of the
International Workshop on Hepatitis B Vaccine, Paris, December 1980. Amsterdam:
Elsevier/North-Holland Biomedical Press. [158]
Prince AM, Vnek J, Stephan W. A new hepatitis B vaccine containing HBeAg in
addition to HBsAg. Devel Biol Stand 54:13-22, 1983. [175]
Vnek J, Hashimoto N, Prince
AM. Immunogenicity of HBeAg in New York
Blood Center Hepatitis B vaccine. Devel Biol Stand 54:217-221, 1983. [176]
Kaufmann R, Mondorf AW, Uthemann H, Bauer H, Prince AM. Hepatitis B vaccine: Safety
and efficacy clinical trial. Devel Biol Stand 54:223-228, 1983. [177]
Kaufmann R, Mondorf AW, Uthemann H, Bauer H, Prince AM. Hepatitis B vaccine:
Safety study in anti-HBs seronegative human volunteers. Devel Biol Stand 54:229-235, 1983. [178]
Prince AM, Brotman B, Purcell RH,
Gerin JL. Infection with hepatitis
B virus after successful immunization with hepatitis B virus vaccine: A final report on safety and immunogenicity
of a bivalent aqueous subunit vaccine.
J Med Virol
15:399-419, 1985. [196]
Prince AM, Vnek J, Brotman
B. An affordable multideterminant
plasma derived hepatitis B virus vaccine. Proc. Symposium on Virus-Associated
Cancers in Africa, Nairobi, IARC Scientific Publications No. 63:355-372, 1984. [200]
Lelie PN, Reesink HW,
Niessen J, Brotman B, Prince AM.
Inactivation of 1015 chimpanzee-infectious doses of hepatitis
B virus during preparation of a heat-inactivated hepatitis B vaccine. J Med
Virol 23:289-295,
1987. [232]
Shata MT, Brotman B,
Perkus M, Lee D-H, Li L, Tricoche N, Murthy K, Prince AM. Attempted therapeutic immunization in a
chimpanzee (Pan troglodytes) chronic HBV carrier with a high viral
load. J Med Primatol. 35:165-171, 2006
VIRUS-FREE
BLOOD DERIVATIVES
Stephan W, Prince AM, Brotman B, van den
Ende MC. Wirksamkeitsnachweis der sterilisation humaner
gerinnungsfaktoren mit β-propiolactone und UV-bestrahlung. In Deutsch, E, Lechner K. (Eds.):
ŅFibrinolyse, Thrombose, Hmostase,Ó Schattauer Verlag Stuttgart, pp. 589-592,
1980. [152]
Stephan W, Prince AM. Efficacy of combined treatment of
factor IX-complex (PPSB) with β-propiolactone (β-PL) and ultraviolet
(UV) irradiation. Protides of Biological Fluids. 28:229-232, 1980.
[153]
Prince AM, Stephan W, Brotman B,
van den Ende MC. Evaluation of the
effect of beta-propiolactone/ultraviolet irradiation (β-PL/UV) treatment
of source plasma on hepatitis transmission by factor IX complex in
chimpanzees. Thrombosis and
Haemostasis
44:138-142, 1980. [155]
Prince AM, Stephan W. Effect of combined
β-propiolactone/ultraviolet irradiation treatment on hepatitis B virus.
Letter to the Editor, Lancet ii: 917, 1980. [157]
Stephan W, Berthold H, Prince
AM. Effect of combined treatment of serum
containing hepatitis B virus with beta-propiolactone and ultraviolet
irradiation. Vox Sang 41:134-138, 1981. [161]
Stephan W, Kotitschke R,
Prince AM,
Brotman B. Long-term tolerance and
recovery of β-propiolactone/ultraviolet (βPL/UV) treated PPSB in
chimpanzees. Thrombosis and Haemostasis 46:511-514, 1981. [162]
Prince AM, Stephan W, Brotman
B. Efficacy of combined treatment
of human plasma with β-propiolactone and UV irradiation. Blutkomponenten und Plasmaersatzmittel. J.R. Kalden and U.D. Koenig (Eds.)
Springer-Verlag, Berlin, Heidelberg, New York, 1982, pp. 68-86. [172]
Kotitschke R, Stephan W, Prince AM. Thrombogenitatstestergebnisse von
kalsterilisiertem PPSB am Schimpansen. Blutkomponenten und Plasmaersatzmittle.
J.R. Kalden and U.D. Koenig (eds.), Springer-Verlag, Berlin, Heidelberg, New
York, 1982, pp. 107-112. [173]
Prince AM, Horowitz B, Brotman B, Huima T,
Richardson L, van den Ende MC. Inactivation of
hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to
Tween 80 and ether. Vox Sang 46:36-43, 1984. [185]
Prince AM, Stephan W, Brotman
B. Inactivation of non-A, non-B
virus infectivity by a beta-propiolactone/ultraviolet irradiation treatment and
aerosil adsorption procedure used for preparation of a stabilized human serum. Vox
Sang
46:80-85, 1984. [186]
Prince AM, Stephan W, Kotitschke
R, Brotman B. Inactivation of
hepatitis and non-A, non-B viruses by combined use of Tween 80,
β-propiolactone, and ultraviolet irradiation. Thrombosis and
Haemostasis 50:534-536,
1983. [201]
Prince AM, Stephan W, Kotitschke
R, Brotman B. Inactivation of the
Hutchinson strain non-A, non-B hepatitis virus by combined use of
β-propiolactone and ultraviolet irradiation. J Med Virol 16:119-125, 1985. [203]
Prince AM, Horowitz B,
Dichtelmueller H, Stephan W, Gallo RC. Quantitative assays for evaluation of
HTLV-III inactivation procedures: tri (N-butyl) phosphate/sodium cholate and
β-propiolactone. Cancer Research 45:4592s-4592s, 1985. [206]
Einarsson M, Prince
AM,
Brotman B. Removal of non-A, non-B
hepatitis-virus from a concentrate of the coagulation factor-II, factor-VII,
factor-IX and factor-X by hydrophobic interaction chromatography. Scand J
Infec Dis
17:141-146, 1985. [207]
Prince AM, Horowitz B, Brotman
B. Inactivation of viruses in
labile blood derivatives 3. Sterilization of hepatitis and HTLV-III viruses by
exposure to tri (N-Butyl) phosphate and sodium cholate. Lancet i:706-710, 1986.
[212]
Prince AM. Effect of heat treatment
of lyophilized blood derivatives on infectivity of human immunodeficiency
virus. Lancet
i: 1280, 1986. [215]
Prince AM, Horowitz B, Horowitz
MS, Zang E. The development of
virus-free labile blood derivatives - a review. Eur J Epidemiol 3:103-118, 1987. [222]
Stephan W, Dichtelmuller
H, Prince AM,
Brotman B, Huima T. Inactivation
of the Hutchinson strain of hepatitis non-A, non-B virus in intravenous
immunoglobulin by β-propiolactone. J Med Virol 26:227-232, 1988. [238]
Horowitz B, Prince AM. Laboratory and preclinical evaluation
of the virus safety of coagulation factor concentrates. Develop Biol
Standard 67:291-302,
1987. [244]
Horowitz B, Williams B,
Rywkin S, Prince AM, Pascual D, Geacintov N, Valinsky J. Inactivation of viruses in blood with
aluminum phthalocyanine derivatives.
Transfusion 31(2): 102-108, 1991. [263]
Horowitz B, Bonomo R, Prince
AM,
Chin SN, Brotman B, Shulman RW.
Solvent/detergent-treated plasma: A virus-inactivated substitute for
fresh frozen plasma. Blood 79:826-831, 1992. [287]
Gao F, Prince AM, Pascual D, Horowitz
B. Enhancement in the safety of
immune globulins prepared from high-risk plasma. Vox Sang 64:204-209, 1993. [290]
Horowitz B, Prince AM, Hamman J, Watklevicz,
C. Viral safety of
solvent/detergent treated blood products. Blood Coagulation and Fibrinolysis 5:S21-S28, 1994. [295]
Prince AM, Horowitz B. Virus safety of pooled fresh-frozen
plasma inactivated by solvent/detergent treatment. Transfusionsmedizin 31: 21-24, 1993. [304]
Lavie G, Mazur Y, Lavie
D, Prince AM,
Pascual D, Liebes L, Levin B, Meruelo D.
Hypericin as an inactivator of infectious viruses in blood products. Transfusion 35:392-400, 1995. [311]
Prince AM, Horowitz B. Viral safety of solvent/detergent
treated intravenous immune globulin. -Letter to the Editor, NEJM 332:1236, 1995. [312]
Prince AM, Pascual D, Meruelo D,
Liebes L, Mazur Y, Dubovi E, Mandel M, Lavie G. Strategies for evaluation of
enveloped virus inactivation in red cell concentrates using hypericin. Photochemistry
and Photobiology
71(2): 188-195, 2000. [336]
Prince AM. Hepatitis viruses and blood
transfusion. Blood Safety and Surveillance, Linden JV and Bianco C (Eds): Marcel
Dekker, Inc., Ch. 12, pp. 279-293, 2001. [338]
CHIMPANZEE
STUDIES
Prince AM. Infection of chimpanzees with hepatitis
B virus. In Vyas, G.N., Perkins, H.A., Schmid R., editors: Hepatitis and
Blood Transfusion,
New York: Grune & Stratton, pp. 403-406, 1972. [173]
Prince AM. Use of chimpanzees as a model for the
study of hepatitis B virus infections. Med Primatol 3:97-109, 1972. [74]
Trepo C, Prince AM. Attempted immunotherapy with dialyzable
transfer in hepatitis B carrier chimpanzees: Induction of delayed
hypersensitivity to hepatitis B surface antigen (HBsAg). In Asher, M. (Ed.): Transfer Factor. New York: Academic Press, pp. 449-456,
1976. [118]
Prince AM, Vnek J, Brotman B, Hashimoto N, van
den Ende MC. Comparative evaluations
of hepatitis B vaccines in chimpanzees and in man. In Vyas G.N., Cohn S.N,
Schmid R. (Eds.): Viral Hepatitis, Philadelphia: Franklin Inst. Press, pp.
507-523, 1978. [138]
Prince AM, Brotman B, van den
Ende MC, Richardson L. Non-A,
non-B hepatitis: Reproduction of disease in chimpanzees and identification of
virus specific antigen and antibody.
In Touraine JL, et al., (Eds.): Transplantation and Clinical
Immunology,
Amsterdam: Excerpta Medica 10:8-17, 1979. [140]
Van den Ende MC, Brotman
B, Prince AM. ŅAn open air holding system for
chimpanzees in medical experiments.Ó Develop. Biol. Standard. Basel: S. Karger
45:95-98, 1980. [148]
Prince AM. ŅThe use of chimpanzees in biomedical
research.Ó Trends in Bioassay Methodology: In vivo, In vitro and
Mathematical Approaches, US Government Printing Office, 1981, pp. 81-97. [160]
Prince AM. Reliability of chimpanzee model for
non-A, non-B hepatitis. Lancet ii: 1134, 1985. [208]
Prince AM, Brotman B, Hannah A,
Donnelly M, Hentschel K, Roth H.
Rehabilitation and release to the wild of chimpanzees used in medical
research. SSC/UUCN Primate Specialist Group, 1986. [218]
Lenz G, Junger H,
Schneider M, Kothe N, Lissner R, Prince AM.
Elimination of pyridoxylated polyhemoglobulin after partial exchange
transfusion in chimpanzees. Biomat Art Cells &
Immob Biotech 19(4): 699-708, 1991. [276]
Lenz G, Junger H, van den Ende R, Brotman B, Prince AM. Hemodynamic effects
after partial exchange transfusion with pyridoxylated polyhemoglobin in
chimpanzees. Biomat Art Cells & Immob Biotech 19(4): 709-718, 1991. [277]
Abe K, Inchauspˇ G, Shikata T, Prince AM. Three different patterns of hepatitis C virus
infection in chimpanzees. Hepatology 15:690-695, 1992. [285]
Luder CGK, Soboslay PT, Prince
AM,
Greene BM, Lucius R, Schultz-Key H.
Experimental onchocerciasis in chimpanzees: cellular responses and
antigen recognition after immunization and challenge with Onchocerca
volvulus
infective third-stage larvae. Parasitology 107:87-97, 1993. [302]
Prince AM, Whalen R, Taylor P,
Brotman B. Protective efficacy of
DNA-based immunization against HBV in newborn chimpanzees. Vaccines 97. Cold Spring Harbor
Laboratory 141-144. [322]
Prince AM, Whalen R, Brotman
B. Successful nucleic acid based
immunization of newborn chimpanzees against hepatitis B virus. Vaccine 15: 916-919, 1997.
[327a]
Prince AM, Brotman B. Biological and immunological aspects of hepatitis C virus infection in chimpanzees. Curr Stud Hematol Blood Transf 62:250-265, 1998. [324]
Prince AM, Brotman B. Methodology
used in DNA-based prophylactic and therapeutic immunization against hepatitis B
virus in chimpanzees in DNA Vaccines. Methods and Protocols. Douglas B. Lowrie and
Robert Whalen, editors. Humana Press Inc., 1999. [325]
Takahashi K, Mishiro S, Prince
AM. Novel hepatitis B virus strain from a
chimpanzee of Central Africa (Pan troglodytes troglodytes) with an unusual
antigenicity of the core protein. Intervirology 44:321-326, 2001. [344]
Prince AM. Nature of non-A, non-B hepatitis
viruses. Letter to the Editor. Lancet i: 1181-1182, 1982. [169]
Brotman B, Prince AM, Huima T, Richardson L,
Pfeifer U. Specificity and
significance of hepatocellular ultrastructural changes in non-A, non-B
hepatitis in chimpanzees. Devel Biol Stand 54:451-462, 1983. [174]
Brotman B, Prince AM, Huima T, Richardson L,
van den Ende MC. Blood-borne
non-A, non-B hepatitis: Lack of infectivity of feces from chimpanzees infected
with a strain producing cytoplastic tubular alterations. J
Infect Dis 147:535-539, 1983. [182]
Brotman B, Prince AM, Huima T, Richardson L,
van den Ende MC, Pfeifer U. Interference between
non-A, non-B and hepatitis virus infection in chimpanzees. Journal of
Medical Virology
11:191-205, 1983. [184]
Prince AM, Huima T, Williams BAA,
Bardina L, Brotman B. Isolation of
a virus from chimpanzees liver cell cultures inoculated with sera containing
the agent of non-A, non-B hepatitis. Lancet ii: 1071-1075, 1984.
[193]
Brotman B, Prince AM, Huima T. Non-A, non-B hepatitis virus: Is there
more than a single blood-borne strain? J Infec Dis 151:618-625, 1985.
[195]
Brotman B, Prince AM. Gamma-glutamyltransferase as a
potential surrogate marker for the detection of the non-A, non-B carrier state.
Vox Sang
54:144-147, 1988. [228]
Brotman B, Boehle W, Prince
AM. Absence of perinatal transmission of
blood-borne non-A, non-B hepatitis virus by chimpanzee with acute and chronic
infection. J Med Virol 28:13-15, 1989. [250]
Prince AM, Brotman B, Huima T,
Kraduledat P, Houghton M, Kuo G, Choo Q-L, Polito A, di Nello R, Nelles
MJ. Distinction between chronic
and self-limited forms of hepatitis C virus infection; in Shitaka, Purcell,
Uchida Viral Hepatitis C, D, and E, pp. 7-16 (Elsevier Science Publishers,
B.V., Amsterdam 1991). [254]
Prince AM, Brotman B, Huima T,
Krauledat P, Houghton M, Kuo G, Choo Q-L, Polito A, di Nello R, Nelles MJ. Use of anti-HCV determination for
diagnosis of chronic HCV infection. Proceedings of 1990 International Symposium
on Viral Hepatitis and Liver Disease:
Contemporary Issues and Future Prospects, Houston 1990, p.450-455
(Williams & Wilkins/Baltimore, 1991). [258]
Inchauspˇ G, Kurokawa D,
Sugitani M, Brinton MA, Andrus L, Brotman B, Prince AM. Isolation and characterization of cDNA
clones from plasma of an HCV infected chimpanzee which cross-hybridize with the
3' terminus of LDV. Proceedings of 1990 International Symposium on Viral
Hepatitis and Liver Disease:
Contemporary Issues and Future Prospects, Houston 1990,
p.382-387 (Williams & Wilkins/Baltimore, 1991). [259]
Nasoff M, Zebedee SL,
Inchauspˇ G, Prince AM.
Identification of an immunodominant epitope within the capsid proteins
of hepatitis C virus. PNAS 88:5462-5466, 1991. [265]
Inchauspˇ G, Abe K,
Zebedee S, Nasoff M, Prince AM.
Use of conserved sequences from Hepatitis C virus for the detection of
viral RNA in infected sera by PCR. Hepatology 14:595-600, 1991. [271]
Prince AM, Brotman B, Huima T,
Pascual D, Jaffery M, Inchauspˇ G.
Immunity in Hepatitis C infection. J Infec Dis 165:438-443, 1992.
[272]
Inchauspˇ G, Zebedee S,
Lee D-H, Sugitani M, Nasoff M, Prince AM.
Genomic structure of the human prototype strain H of hepatitis C:
comparison with American and Japanese isolates. PNAS 88:10292-10296, 1991.
[274]
Sugitani M, Inchauspˇ G,
Shindo M, Prince AM. Sensitivity
of serological assays for detection of HCV viremic blood donors. Lancet 339:1018-1019, 1992.
[282]
Prince AM, Huima-Byron T, Parker
TS, Levine DM. Visualization of
hepatitis C virions, and putative defective interfering particles, isolated
from low-density lipoproteins. J Viral Hep 3:11-17, 1996. [314]
Wang Y-F, Brotman B, Andrus L, Prince AM. Immune response to epitopes of hepatitis C virus (HCV) structural proteins in HCV-infected humans and chimpanzees. J Infec Dis 173:808-821, 1996. [317]
Wyatt CA, Andrus L,
Brotman B, Huang F, Lee D-H, Prince AM. Immunity in chimpanzees chronically
infected with hepatitis C virus: Role of minor quasispecies in reinfection. J
Virol
72:1725-1730, 1998. [327]
Cohard M, Liu Q, Perkus
M, Gordon E, Brotman B, Prince AM.
Hepatitis C virus-specific CTL responses in PBMC from chimpanzees with
chronic hepatitis C: determination of CTL and CTL precursor frequencies using a
recombinant canarypox virus (ALVAC). J Immunol Method 214:121-129, 1998.
[328]
Prince AM, Brotman B, Lee D-H,
Ren L, Moore BS, Scheffel JW. Significance of the anti-E2 response in
self-limited and chronic hepatitis C virus infections in chimpanzees and in
humans. J Infec Dis 180:987-991, 1999. [332]
Pancholi P, Liu Q, Tricoche N, Zhang P, Perkus M, Prince AM. DNA prime-canarypox
boost with polycistronic hepatitis C virus (HCV) genes generates potent immune
responses to HCV structural and nonstructural proteins. J Infect Dis 182:18-27, 2000. [337]
Pancholi P, Lee D-H, Liu Q, Tackney C, Taylor P, Perkus M, Andrus L, Brotman B, Prince AM. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 33:448-454, 2001. [339]
Shata MT, Anthony DD, Carlson NL, Andrus L, Brotman B, Tricoche N, McCormack P, Prince AM. Characterization of the immune response against hepatitis C infection in recovered, and chronically HCV infected chimpanzees. J of Viral Hepatitis 9(6):400-410, 2002. [350]
Cohard M, Liu Q, Perkus M, Gordon E, Brotman B, Prince AM. Hepatitis C virus-specific CTL responses in PBMC from chimpanzees with chronic hepatitis C: determination of CTL and CTL precursor frequencies using a recombinant canarypox virus (ALVAC). J Immunol Method 214:121-129, 1998. [328]
Shata MT, Tricoche N, Perkus M, Tom D, Brotman
B, McCormack P, Pfahler W, Lee D-H, Tobler LH, Busch M, Prince AM. Exposure to low infective doses of HCV
induces cellular immune responses without consistently detectable viremia or
seroconversion in chimpanzees. Virology 314: 601-616, 2003. [352]
Prince AM, Pawlotsky
J-M, Soulier A, Tobler L, Brotman B, Pfahler W, Lee D-H, Li L, Shata MT. Hepatitis C virus replication kinetics
in chimpanzees with self-limited and chronic infections. J of Viral Hep 11:236-242, 2004. [355]
Youn
J-W, Park S-H, Lee CG, Yang S-H, Jin HT, Shata MT, Prince AM, Sung YC.
Sustained
E2 antibody response correlates with reduced peak viremia after hepatitis C
infection in chimpanzee. Hepatology, In Press
Shata MT, Shan M,
Tricoche N, Prince AM. HCV-specific high avidity T cells are predominantly
present in recovered HCV-infected chimpanzees. Submitted to Infection and Immunity, 2004.
Alfred M. Prince, Betsy Brotman,
Dong-Hun Lee, Wolfram Pfahler, Nancy Tricoche, Linda Andrus, Mohamed T. Shata.
Protection against chronic hepatitis C virus infection after rechallenge with
homologous, but no heterologous, genotypes in a chimpanzee model. J Inf Dis
192: 1701-9, 2005
Yao ZQ, Shata MT,
Tricoche N, Shan MM, Brotman B, Pfahler W, Hahn YS, Prince AM. gC1qR expression in
chimpanzees with resolved and chronic infection: potential role of HCV
core/gC1qR-mediated T cell suppression in the outcome of HCV infection.
Virology, In Press
ONCHOCERCA
VOLVULUS
Prince AM, Albiez EJ, van den
Ende MC. Onchocerca volvulus: transplantation of
adult worms in chimpanzees. Tropenmed Parasitol 36:63-122, 1985. [204]
Weiss N, van den Ende
MC, Albiez EJ, Barbiero V, Forsyth K, Prince AM. Detection of serum antibodies and
circulating antigens in a chimpanzee experimentally infected with Onchocerca
volvulus.
Trans Roy Soc Trop Med 40:587-591, 1986. [219]
Miller KM, Hotze C,
Brotman B, Prince AM. An economical
procedure for screening of hybridoma supernatant for surface reactive
antibodies to filarial larvae. Trop Med Parasitol 41(2): 221-222, 1990.
[253]
Johnson EH, Brotman B,
Browne J, Prince AM. Onchocerca
volvulus:
In vitro killing of microfilaria by neutrophils and eosinophils from
experimentally infected chimpanzees. Trop Med Parasitol 42:351-355, 1991. [273]
Prince AM, Brotman B, Johnson Jr.
EH, Smith A, Pascual D, Lustigman S.
Onchocerca volvulus: Immunization of chimpanzees with x-irradiated
third-stage (L3) larvae. Exp Parasitol 74:239-250, 1992. [280]
Irvine M, Huima T, Prince
AM,
Lustigman S. Identification and
characterization of an Onchocerca volvulus c DNA clone encoding a highly
immunogenic calponin-like protein. Mol Biochem Parasitol 65:135-146, 1994. [308]
HIV
Eichberg JW, Lee DR,
Allan JS, Cobb KE, Barbosa LH, Nemo GJ, Prince AM. In utero infection of an infant
chimpanzee with HIV. Letter to the
Editor. N. Eng. J. Med. 319:722-723, 1988. [243]
Robinson WE Jr.,
Montefiori DC, Mitchell WM, Prince AM, Alter HJ, Dreesman GR, Eichberg JW.
Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1)
infection in vitro by serum from HIV-1-infected and passively immunized
chimpanzees. PNAS
86: 4710-4714, 1989. [249]
Ward RHR, Capon DJ, Jett
CM, Murthy KK, Mordenti J, Lucas C, Frie SW, Prince AM, Green JD, Eichberg
JW. Prevention of HIV-1 IIIB
infection in chimpanzees by CD4 immunoadhesin. Nature 352: 434-436, 1991. [269]
Prince AM. Chimpanzee pathogenic strains of HIV
type 1. Letter to the Editor, AIDS Res. Hum. Retro. 13: 1259, 1997 [326].
Prince AM, Andrus L. AIDS vaccine trials in chimpanzees.
Letter to the Editor, Science 282:2195, 1998. [329]
Prince AM, Allan J, Andrus L,
Brotman B, Eichberg J, Fouts R, Goodall J, Marx P, Murthy KK, McGreal S, Noon
C. Virulent HIV strains,
chimpanzees, and trial vaccines. Letter to the Editor, Science 283:1117-1118, 1999.
[321]
Prince AM, Brotman B, Lee D-H, Andrus L, Valinsky
J, Marx P. Lack of evidence for HIV Type 1-related SIVcpz infection in captive
and wild chimpanzees (Pan troglodytes verus) in West Africa. Aids Research and Human Retroviruses 18(9):657-660,
2002. [348]
HIV IMMUNE
GLOBULIN
Prince AM, Horowitz B, Baker L,
Shulman RW, Ralph H, Valinsky J, Cundell A, Brotman B, Boehle W, Rey F, Reesink
H, Lelie N, Tersmette M, Miedema F, Barbosa L, Nemo G, Nastala CL, Langlois AJ,
Allan JS, Lee DR, Eichberg JW.
Failure of an HIV immune globulin to protect chimpanzees against
experimental challenge with HIV. PNAS 85:6944-6948, 1988. [236]
Prince AM, Saunders A, Pascual D,
Robonsin WEJ, Andrus L, Bianco C, Montefiore DC, Mitchell WN. Mechanisms for the failure of passively
administered neutralizing antibodies to protect against HIV challenge in the
chimpanzee model. Vaccines '89 Channock RM., Lerner RA, Brown F, Ginsberg H,
(eds.). Cold Spring Harbor, 1989. [241]
Prince AM, Horowitz B, Shulman
RW, Pascual D, Hewlett I, Epstein J, Eichberg JW. Apparent prevention of HIV infection by HIV immunoglobulin
given prior to low-dose HIV challenge. Vaccines '90, Channock RM, Lerner
RA, Brown F and Ginsberg H, (eds.). Cold Spring Harbor, 1990, 347-351. [257]
Prince AM, Reesink H, Pascual D,
Horowitz B, Hewlett I, Murthy KK, Cobb KE, Eichberg JW. Prevention of HIV infection by passive
immunization with HIV immunoglobulin. AIDS Res Hum Retro 7(12): 971-973, 1991.
[270]
Prince AM, Pascual D, Horowitz B,
Reesink H, Hewlett I, Murthy KK, Cobb KE, Eichberg JW. Passive immunization
against HIV. Vaccines '92 Channock RM, Lerner RA, Brown F and Ginsberg H,
(eds.). Cold Spring Harbor, 1992, 85-87. [275]
Andrus L, McCarthy M,
Cobb KE, McCormack P, Murthy KK, Pascual D, Prince AM. Passive immunization against HIV-1
infection using HIV immune globulins (HIVIG). Huiti¸me
Colloque Des Cent Gardes, 1993. [306]
Prince AM. Research costs: man versus chimpanzee. J Med
Primatol
13: 231-232, 1984. [202]
Prince AM, Moor-Jankowski J,
Eichberg JW, Schellekens H, Mauler RF, Girard M, Goodall J. Chimpanzees and
AIDS research, Commentary. Nature 333: 513, 1988. [235]
Prince AM, Goodall J, Brotman B, Dienske H,
Schellekens H, Eichberg JW. Appropriate conditions
for maintenance of chimpanzees in studies with blood-borne viruses: An
epidemiologic and psychosocial perspective. J Med Primatol 18: 27-42, 1989. [247]
Prince AM, Brotman B, Garnham B,
Hannah AC. Enrichment,
rehabilitation, and release of chimpanzees used in biomedical research. Lab
Animal
19(5): 29-37, 1990. [256]
van Akker R, Balls M,
Eichberg JW, Goodall J, Heeney JL, Osterhaus ADME, Prince AM, Spruit I. Chimpanzees
in AIDS research: A biomedical and bioethical perspective. J Med Primatol 22: 390-392, 1993. [294]
Prince AM. Is the conduct of medical research on
chimpanzees compatible with their rights as a near-human species? Between the Species 9(1):48-49, 1993. [301]
REVIEWS
Prince AM. Emerging Infections (Book Review) in JAMA 270:384, 1993. [292]
Prince AM. Challenges for
development of hepatitis C virus vaccines. FEMS Microbiology Reviews 14:273-278, 1994. [293]
Prince AM, Mahoney R, Maynard
J. Prevention of hepatitis B
infection in Viral Hepatitis and Liver Disease pp. 517-519, Nishioka K, Suzuki
H, Mishiro S, Oda T (eds.). Springer-Verlag, Tokyo 1994. [296]
Prince AM. Prevention. Proceedings
of the International Symposium on Hepatitis and Liver Diseases Springer Verlag, 1993.
[297]
Prince AM. Blood Products. Nature 379:14, 1996 (Letter).
[316]
Prince AM. Prevention of liver cancer and cirrhosis by vaccines. Clinics in Laboratory Medicine 16:493-505, 1996. [318]
Prince AM.
Perspectives on prophylactic and therapeutic immunization against
hepatitis B and C viruses. Transfus
Clin Biol
8:467-470, 2001. [343]
Prince AM, Shata MT. Immunoprophylaxis of hepatitis C virus infection. Clinics in Liver Disease 5:1091-1103, 2001. [345]
Ganem D, Prince
AM. Hepatitis B
virus infection--natural history and clinical consequences. N Engl J Med. 350:1118-29, 2004. Erratum in N Engl J Med. 351:351, 2004.